Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Keysight Technologies enters the final stretch of its fiscal year with momentum firmly intact, a fresh bullish move from Goldman Sachs, and options traders leaning more constructively than they have in months.
The standout event this week is the Goldman Sachs call. Mark Delaney raised his price target to $487 from $452 on Tuesday, maintaining a Buy rating. That move came with the stock already up 7.6% on the week to $388.03, extending a remarkable 18.6% gain over the past month. The new Goldman target sits 25% above the current price, well above the Street consensus of $418, and signals that at least one bellwether house sees the rally as having further to run. The broader analyst community swung constructive in August after the last earnings print, with JP Morgan, Morgan Stanley, UBS, Barclays and Wells Fargo all raising targets in the $400 to $440 range. Most ratings remain Overweight or Buy. Truist is the notable holdout at Hold with a $400 target, roughly where the stock is now.
Options positioning reinforces the bullish tilt. The put/call ratio has dropped to 0.566, its lowest reading in the past year, sitting more than one standard deviation below its 20-day average of 0.60. That means call demand is running well ahead of put demand, the mirror image of a defensive posture. The contrast with September is sharp: the ratio was near 0.69 in early September before the rally accelerated, and it has compressed steadily since. Borrow conditions confirm there is no meaningful short pressure underpinning any of this. Short interest is just 1.4% of the free float, down 20% over the past month. Availability is essentially unlimited, with 168 million shares available to lend against roughly 2.4 million currently borrowed. Cost to borrow is 0.42%, a level consistent with a totally routine borrow. None of the short metrics are the story here.
Valuation has re-rated sharply alongside the price. The P/E multiple has expanded roughly 3.8 points over the past 30 days to 29.1x, and price-to-book has moved up by 1.2x to 8.2x over the same period. EV/EBITDA sits near 24x. These are not bargain multiples for an instrument company, and they reflect the degree to which the market is pricing in a recovery. The ORTEX factor scores tell a similar story: the short score rank is high at 83 (meaning short sellers are notably absent relative to the broader universe), but the forward earnings growth score sits at just 22 out of 100, a reminder that consensus estimates for the year ahead are not particularly elevated. EPS momentum over 90 days scores at 70, a reasonable reading, but the 12-month forward year-on-year increase metric is the weakest pillar in the factor profile.
The insider picture is worth noting, though it reads more like routine housekeeping than a directional signal. CEO Satish Dhanasekaran sold 3,000 shares on September 30 for roughly $1.1 million. CFO Neil Dougherty sold 2,000 shares on September 21. Neither sale was disclosed as part of a pre-arranged 10b5-1 plan, which typically reduces the informational content of a trade. Net insider sales over 90 days total around $4.1 million across multiple executives. Taken at face value this is a modest net negative, but the scale is small relative to the stock's move and the absence of any buying is largely offset by the stock's strong price performance over the period in which the sales occurred.
Retail attention is also running above recent norms. Wikipedia traffic for Keysight is tracking at a z-score of 1.6 against its own 90-day history, placing it in the upper range of its own attention distribution. This is a sentiment and attention indicator rather than a revenue signal, but it is consistent with the broader pickup in investor interest that the price action reflects.
The next earnings event is scheduled for November 24. Given that the stock fell 11.5% on the day of its August print and gave back a similar amount over the following five days, the setup heading into that report will be worth watching closely, particularly how the Goldman target revision and the re-rated valuation hold up as the quarter progresses.
See the live data behind this article on ORTEX.
Open KEYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
